CA3242277A1 - Crystalline salt form of ep4 antagonist - Google Patents

Crystalline salt form of ep4 antagonist

Info

Publication number
CA3242277A1
CA3242277A1 CA3242277A CA3242277A CA3242277A1 CA 3242277 A1 CA3242277 A1 CA 3242277A1 CA 3242277 A CA3242277 A CA 3242277A CA 3242277 A CA3242277 A CA 3242277A CA 3242277 A1 CA3242277 A1 CA 3242277A1
Authority
CA
Canada
Prior art keywords
antagonist
salt form
crystalline salt
carboxamido
difluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242277A
Other languages
English (en)
French (fr)
Inventor
Farid Benayoud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA3242277A1 publication Critical patent/CA3242277A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3242277A 2021-12-23 2022-12-22 Crystalline salt form of ep4 antagonist Pending CA3242277A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163293183P 2021-12-23 2021-12-23
US63/293,183 2021-12-23
PCT/US2022/053842 WO2023122289A1 (en) 2021-12-23 2022-12-22 Crystalline salt form of ep4 antagonist

Publications (1)

Publication Number Publication Date
CA3242277A1 true CA3242277A1 (en) 2023-06-29

Family

ID=85222399

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242277A Pending CA3242277A1 (en) 2021-12-23 2022-12-22 Crystalline salt form of ep4 antagonist

Country Status (7)

Country Link
US (1) US20250051285A1 (enExample)
EP (1) EP4452949A1 (enExample)
JP (1) JP2024545695A (enExample)
KR (1) KR20240124927A (enExample)
CN (1) CN118414328A (enExample)
CA (1) CA3242277A1 (enExample)
WO (1) WO2023122289A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3061751A1 (en) 2010-09-21 2016-08-31 Eisai R&D Management Co., Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
JP2024545695A (ja) 2024-12-10
WO2023122289A1 (en) 2023-06-29
US20250051285A1 (en) 2025-02-13
CN118414328A (zh) 2024-07-30
KR20240124927A (ko) 2024-08-19
EP4452949A1 (en) 2024-10-30

Similar Documents

Publication Publication Date Title
DE60307607T2 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
MY142491A (en) A process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salts, useful as adrenoreceptor agonists
EP2292591A3 (en) Process for the preparation of cyclopropyl derivatives
CA2350956A1 (en) New crystals of celecoxib
ATE151418T1 (de) Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
NZ606629A (en) Benzoic acid derivatives
IL318601A (en) Improved synthesis of a key intermediate of the KRAS inhibitor compound G12C
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
ZA202203677B (en) Carboxylic acid derivative-substituted iminoaryl compound, preparation method therefor, herbicidal composition and use thereof
EP2567955A3 (en) Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these
EP4349827A4 (en) Acid salt of a crystalline CSF-1R inhibitor and method of preparation and use thereof
CA2471952A1 (en) Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
GEP20074138B (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
YU71500A (sh) Metod za dobijanje 4-karboksiamino-2-supstituisanog -1,2,3,4-tetrahidrohinolina
US20100267765A1 (en) Pharmaceutical Compositions and Methods for CCR5 Antagonists
HUE048936T2 (hu) Glikopirrolátot és egy béta2 adrenoreceptor agonistát tartalmazó gyógyszerkészítmény
CA2442227A1 (en) Ccr5 antagonists useful for treating aids
NO20074188L (no) Prosess for fremstilling av montelukast og mellomprodukter for det
MXPA04002036A (es) Hidratos cristalinos de derivados de anilida de acido nicotinico.
EP1572173B1 (en) Alpha-2-delta ligand to treat lower urinary tract symptoms
MX2023004046A (es) Proceso para la preparacion de esteres, amidas y nitrilos de acido 5-(1-cianociclopropil)-piridin-2-carboxilico.
CA2206748A1 (en) Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl)phenyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)acetylamino)-3-phenylpropionate
NO20060379L (no) Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre
AU2002328835A1 (en) Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives, intermediates thereof and methods for their preparation
CA2477720A1 (en) Quinoline derivatives

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213